| References: |
BML-277 (C 3742) is a selective Chk2 (checkpoint kinase 2) inhibitor with an IC50 of 15 nM.BML-277 protects T cells from apoptosis by controlling the response of p53 to radiation-induced DNA breaks. This is suggestive of BML-277's use as an adjuvant for radiation therapy in cancer. BML-277 is 1000-fold more selective toward Chk2 serine/threonine kinase than for Chk1 and Cdk1/B kinases. It has also been found to weakly inhibit 31 other kinases For the detailed information of BML-277, the solubility of BML-277 in water, the solubility of BML-277 in DMSO, the solubility of BML-277 in PBS buffer, the animal experiment (test) of BML-277, the cell expriment (test) of BML-277, the in vivo, in vitro and clinical trial test of BML-277, the EC50, IC50,and affinity,of BML-277, For the detailed information of BML-277, the solubility of BML-277 in water, the solubility of BML-277 in DMSO, the solubility of BML-277 in PBS buffer, the animal experiment (test) of BML-277, the cell expriment (test) of BML-277, the in vivo, in vitro and clinical trial test of BML-277, the EC50, IC50,and affinity,of BML-277, Please contact DC Chemicals. |
